Valneva News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Orderbuch			Analysen
Historisch

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Orderbuch

Analysen

Historisch

04.12.23	Pfizer and Valneva Complete Recruitment for Phase 3 VALOR Trial for Lyme Disease Vaccine Candidate, VLA15 (GlobeNewswire)
04.12.23	Valneva Reports Positive 24-Month Antibody Persistence Data for its Single-Shot Chikungunya Vaccine IXCHIQ® (GlobeNewswire)
27.11.23	EMA Accepts Valneva’s Chikungunya Vaccine Marketing Authorization Application for Accelerated Assessment (GlobeNewswire)
15.11.23	Valneva Announces the Availability of Documentation for its Extraordinary General Meeting including Planned Changes to its Future Board of Directors (GlobeNewswire)
13.11.23	Valneva Reports Positive Pivotal Phase 3 Immunogenicity Data in Adolescents for its Single-Shot Chikungunya Vaccine Candidate (GlobeNewswire)
10.11.23	Valneva Announces U.S. FDA Approval of World’s First Chikungunya Vaccine, IXCHIQ® (GlobeNewswire)
09.11.23	Valneva Reports Nine-Month 2023 Financial Results and Provides Corporate Updates (GlobeNewswire)
07.11.23	Valneva to Present and Hold Investor Meetings at the Jefferies London Healthcare Conference (GlobeNewswire)
06.11.23	VALNEVA Declaration of shares and voting rights: October 31, 2023 (GlobeNewswire)
25.10.23	Valneva Submits Chikungunya Vaccine Marketing Application to EMA and Announces CHMP Accelerated Assessment (GlobeNewswire)
11.10.23	Valneva to Present on Chikungunya at Several Leading Scientific Conferences (GlobeNewswire)
05.10.23	VALNEVA - Declaration of shares and voting rights: September 30, 2023 (GlobeNewswire)
25.09.23	Valneva Announces New IXIARO® Supply Contract with the U.S. Government Worth a Minimum of $32 Million (GlobeNewswire)
21.09.23	Valneva Reports Half Year 2023 Financial Results and Provides Corporate Updates (GlobeNewswire)
07.09.23	Valneva and Pfizer Report Positive Pediatric and Adolescent Phase 2 Booster Results for Lyme Disease Vaccine Candidate (GlobeNewswire)
06.09.23	VALNEVA Declaration of shares and voting rights: August 31, 2023 (GlobeNewswire)
31.08.23	Valneva to Participate in Investor Conferences in the United States and Europe in September 2023 (GlobeNewswire)
29.08.23	Health Canada Accepts Valneva’s Chikungunya Vaccine License Application for Review (GlobeNewswire)
28.08.23	Valneva Reports Positive Initial Phase 3 Safety Data in Adolescents for its Single-Shot Chikungunya Vaccine Candidate (GlobeNewswire)
17.08.23	Valneva Announces Extension of Existing Loan Agreement (GlobeNewswire)
14.08.23	Valneva Announces PDUFA Date Extension for Chikungunya Virus Vaccine Candidate (GlobeNewswire)
03.08.23	VALNEVA Declaration of shares and voting rights - July 31, 2023 (GlobeNewswire)
05.07.23	VALNEVA - Declaration of shares and voting rights: June 30, 2023 (GlobeNewswire)
22.06.23	Valneva Supervisory Board Recommends Transition from a Two-Tier Governance Model to a Board of Directors (GlobeNewswire)
21.06.23	Valneva Announces Successful Outcome of its AGM and the Appointment of Pfizer’s Former Vaccine R&D Head to its Supervisory Board (GlobeNewswire)
13.06.23	Valneva Announces Publication of its Chikungunya Vaccine Candidate Phase 3 Data in The Lancet (GlobeNewswire)
07.06.23	VALNEVA - Declaration of shares and voting rights: May 31, 2023 (GlobeNewswire)
31.05.23	Valneva to Present and Hold Investor Meetings at Upcoming Conferences in June (GlobeNewswire)
31.05.23	Valneva Announces the Availability of Documentation for its Shareholder Meeting (GlobeNewswire)
30.05.23	Valneva Files for Chikungunya Vaccine Authorization with Health Canada (GlobeNewswire)
04.05.23	VALNEVA - Declaration of shares and voting rights - April 30, 2023 (GlobeNewswire)
04.05.23	Valneva Reports First Quarter 2023 Financial Results and Provides Corporate Updates (GlobeNewswire)
06.04.23	VALNEVA - Declaration of shares and voting rights - March 31, 2023 (GlobeNewswire)
31.03.23	Valneva Announces Filing of 2022 Universal Registration Document and US Form 20-F (GlobeNewswire)
30.03.23	Valneva to Present on its Chikungunya Vaccine Candidate and Host a Roundtable at the 23rd World Vaccine Congress in Washington D.C. (GlobeNewswire)
23.03.23	Valneva Reports Full Year 2022 Results and Provides Corporate Updates (GlobeNewswire)
06.03.23	VALNEVA - Declaration of shares and voting rights - February 28, 2023 (GlobeNewswire)
02.03.23	Valneva Provides Clinical and Regulatory Updates for its COVID-19 Vaccine VLA2001 (GlobeNewswire)
01.03.23	Valneva to Present at the Cowen 43rd Annual Healthcare Conference (GlobeNewswire)
20.02.23	FDA Accepts Valneva’s Chikungunya Vaccine License Application for Priority Review (GlobeNewswire)
17.02.23	Pfizer and Valneva Issue Update on Phase 3 Clinical Trial Evaluating Lyme Disease Vaccine Candidate VLA15 (GlobeNewswire)
16.02.23	Valneva Reports Full Year 2022 Revenue and Cash, Provides First 2023 Guidance (GlobeNewswire)
14.02.23	Valneva Completes Enrollment for Adolescent Phase 3 Trial of Single-Shot Chikungunya Vaccine Candidate (GlobeNewswire)
29.01.19	Valneva CEO Interview - Stratégie du Groupe (video) (PR Newswire)
29.01.19	Valneva CEO Interview - Group Strategy (video) (PR Newswire)
29.01.19	Valneva CEO Interview - Group Strategy (video) (PR Newswire)
07.01.19	Ad hoc: Valneva gibt Absicht bekannt, seine Notierung an der Wiener Börse zu beenden (GlobeNewswire)
31.08.17	Valneva Interview du PDG - Résultats du premier semestre 2017 (video) (PR Newswire)
31.08.17	Valneva CEO Interview - Half Year 2017 Earnings (video) (PR Newswire)
31.08.17	Valneva CEO Interview - Half Year 2017 Earnings (video) (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Zurich Insur Gr	547.60	3.13 %	K V
Logitech Intl	70.26	2.57 %	K V
Givaudan	3’919.00	1.45 %	K V
ABB	49.58	1.08 %	K V
Swiss Re	127.20	0.99 %	K V
Holcim	89.86	-0.24 %	K V
Sika	229.00	-0.35 %	K V
Swisscom	505.50	-0.49 %	K V
Nestle	75.96	-0.73 %	K V
CieFinRichemont	117.65	-0.80 %	K V

mehr

21.11.24		Freundlicher Handel: TecDAX letztendlich im Plus
21.11.24		SDAX aktuell: SDAX zum Handelsende auf grünem Terrain
21.11.24		Zuversicht in Frankfurt: LUS-DAX beendet die Donnerstagssitzung im Plus
21.11.24		Gewinne in Frankfurt: Letztendlich Pluszeichen im DAX
21.11.24		S&P 500-Titel Moderna-Aktie: So viel hätte eine Investition in Moderna von vor einem Jahr gekostet
21.11.24		Donnerstagshandel in Frankfurt: DAX mit Kursplus
21.11.24		Minuszeichen in Frankfurt: SDAX am Nachmittag leichter
21.11.24		TecDAX aktuell: TecDAX gibt am Donnerstagnachmittag nach

21.11.24

Freundlicher Handel: TecDAX letztendlich im Plus

21.11.24

SDAX aktuell: SDAX zum Handelsende auf grünem Terrain

21.11.24

Zuversicht in Frankfurt: LUS-DAX beendet die Donnerstagssitzung im Plus

21.11.24

Gewinne in Frankfurt: Letztendlich Pluszeichen im DAX

21.11.24

S&P 500-Titel Moderna-Aktie: So viel hätte eine Investition in Moderna von vor einem Jahr gekostet

21.11.24

Donnerstagshandel in Frankfurt: DAX mit Kursplus